CN117752711A - Composition for reducing hyperuricemia as well as preparation method and application thereof - Google Patents
Composition for reducing hyperuricemia as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN117752711A CN117752711A CN202311800998.9A CN202311800998A CN117752711A CN 117752711 A CN117752711 A CN 117752711A CN 202311800998 A CN202311800998 A CN 202311800998A CN 117752711 A CN117752711 A CN 117752711A
- Authority
- CN
- China
- Prior art keywords
- hyperuricemia
- composition
- parts
- reducing
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 53
- 244000228451 Stevia rebaudiana Species 0.000 claims abstract description 35
- 235000006092 Stevia rebaudiana Nutrition 0.000 claims abstract description 35
- 240000008672 Gynura procumbens Species 0.000 claims abstract description 30
- 235000018457 Gynura procumbens Nutrition 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 30
- 238000000605 extraction Methods 0.000 claims abstract description 20
- 235000012055 fruits and vegetables Nutrition 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 66
- 108090000790 Enzymes Proteins 0.000 claims description 58
- 102000004190 Enzymes Human genes 0.000 claims description 58
- 229940088598 enzyme Drugs 0.000 claims description 58
- 239000000284 extract Substances 0.000 claims description 34
- 239000011259 mixed solution Substances 0.000 claims description 34
- 108010059892 Cellulase Proteins 0.000 claims description 30
- 229940106157 cellulase Drugs 0.000 claims description 30
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 244000237330 gutta percha tree Species 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 27
- 239000002131 composite material Substances 0.000 claims description 21
- 239000008213 purified water Substances 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 230000000415 inactivating effect Effects 0.000 claims description 11
- 238000004140 cleaning Methods 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 230000001376 precipitating effect Effects 0.000 claims description 10
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims description 8
- 240000003394 Malpighia glabra Species 0.000 claims description 8
- 235000014837 Malpighia glabra Nutrition 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 3
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 24
- 229930003944 flavone Natural products 0.000 abstract description 24
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 24
- 235000011949 flavones Nutrition 0.000 abstract description 24
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 24
- 244000046146 Pueraria lobata Species 0.000 abstract description 22
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 17
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 238000012546 transfer Methods 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000005265 energy consumption Methods 0.000 abstract description 2
- 241000208689 Eucommia ulmoides Species 0.000 abstract 2
- 230000000052 comparative effect Effects 0.000 description 17
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 16
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 229940116269 uric acid Drugs 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 9
- 229940109239 creatinine Drugs 0.000 description 8
- 241000167854 Bourreria succulenta Species 0.000 description 7
- 235000019693 cherries Nutrition 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 210000005084 renal tissue Anatomy 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000220317 Rosa Species 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 229960000285 ethambutol Drugs 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108010002430 hemicellulase Proteins 0.000 description 2
- -1 puerarin Chemical class 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 241000735527 Eupatorium Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000212941 Glehnia Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000000899 Gutta-Percha Substances 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000000342 Palaquium gutta Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 239000009759 San-Chi Substances 0.000 description 1
- 241000223261 Trichoderma viride Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229920000588 gutta-percha Polymers 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine health care, and particularly relates to a composition for reducing hyperuricemia, and a preparation method and application thereof. The composition for reducing hyperuricemia comprises the following components in parts by weight: 10-25 parts of gynura procumbens, 10-15 parts of radix puerariae, 8-12 parts of stevia rebaudiana, 5-15 parts of eucommia ulmoides leaves and 0.1-3 parts of fruit and vegetable powder. The invention obtains the composition for reducing the hyperuricemia through scientifically proportioning the gynura procumbens, the kudzuvine root, the stevia rebaudiana, the eucommia ulmoides leaf and the fruit and vegetable powder, the composition formula can not generate toxic or side effect after long-term use, the use is safer, the preparation method of the composition for reducing the hyperuricemia is provided, the production cost is low, the energy consumption is effectively saved, the average value of the total flavone content of the prepared composition for reducing the hyperuricemia is 10.88mg/g, the transfer rate of the total flavone is 89.48%, and the extraction effect is better.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine health care, and particularly relates to a composition for reducing hyperuricemia, and a preparation method and application thereof.
Background
Hyperuricemia (HUA) refers to the condition of normal diet that results from excessive uric acid production and/or hypovolemia in the body. The male with the fasting blood uric acid level of two times a day is higher than 420 mu mol/L, and the female is higher than 360 mu mol/L, thus the hyperuricemia is obtained. In recent years, due to changes in lifestyle of people, intake of a large amount of high-protein and high-fat diets, excessive drinking, night cooking, lack of exercise and other bad habits, the occurrence rate of hyperuricemia is increased increasingly, and a trend of younger is presented, febuxostat and allopurinol which inhibit uric acid generation, probenecid and tribromone which promote uric acid excretion and the like are clinically adopted to reduce blood uric acid, but multiple side effects such as gastrointestinal discomfort, rash, bone marrow suppression, liver and kidney function damage and the like are generated after long-term administration, so that clinical popularization and application are affected. Therefore, further research and development of a pharmaceutical preparation with good effect of reducing blood uric acid and small toxic and side effects is needed.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a composition for reducing high uric acid, a preparation method and application thereof, which scientifically mixes gynura procumbens, kudzuvine root, stevia rebaudiana, eucommia ulmoides leaves and fruit and vegetable powder to obtain the composition for reducing high uric acid.
In order to solve the technical problems of the invention, the invention adopts the following technical scheme:
the invention aims at providing a composition for reducing hyperuricemia, which comprises the following components in parts by weight: 10-25 parts of gynura procumbens, 10-15 parts of radix puerariae, 8-12 parts of stevia rebaudiana, 5-15 parts of eucommia ulmoides leaves and 0.1-3 parts of fruit and vegetable powder.
The gynura procumbens has flat nature and sweet and light taste, is a unique herbal plant which is eaten by crude drugs for years and can be eaten by the sanchi of the asteraceae, has active ingredients such as organic calcium, neochlorogenic acid, flavone, alkaloid, flavone, sesquiterpene and the like, has the effects of dredging meridian passage, diminishing inflammation, relieving cough, removing blood stasis, reducing swelling, promoting blood circulation, promoting granulation and the like, and is mainly used for treating traumatic injury, rheumatic arthralgia and gout.
The kudzuvine root is an important natural plant with homology of medicine and food in China, has the name of 'nan kudzuvine root and glehnia root', contains isoflavone compounds such as puerarin, soyabean extract, soyabean glycoside and the like, has various pharmacological effects, and has the functions of relieving muscle and fever, promoting the production of body fluid to quench thirst, promoting eruption, raising yang and relieving diarrhea, activating the channels and collaterals and relieving alcoholism.
Stevia rebaudiana is the leaf of stevia rebaudiana of the genus eupatorium of the family Compositae, native to the Aban Bayesian mountain at the boundary of Paraguay and Brazil in south america, was originally used by local people to mask the bitter taste of herbal medicines, was successfully introduced from japan in 1976, was currently the country of production and export where the area of stevia rebaudiana planting is the largest in the world, was introduced in Beijing, hebei, shanxi, jiangsu, fujian, hunan, yunnan and other places, and was widely used in industries such as foods, pharmaceuticals and cosmetics. In recent years, scholars at home and abroad sequentially find that the stevia rebaudiana extract has pharmacological activities of resisting oxidation, bacteria, viruses and tumors, assisting in treating diabetes, regulating lipid metabolism, regulating immunity and the like.
The eucommia ulmoides leaf is a dry leaf of eucommia ulmoides belonging to eucommia ulmoides family, is a medicinal and edible raw material, has the same effective components and pharmacological actions as eucommia ulmoides bark, has more than 70 separated and identified organic compounds, wherein the inorganic mineral elements are not less than 15, and can be roughly divided into iridoids, lignans, flavonoids, gutta-percha, phenylpropanoids, phenols, amino acids, polysaccharides, fatty acids and vitamins. Eucommia ulmoides She Xingwei pungent and warm. It has effects in nourishing liver and kidney, and strengthening tendons and bones. Can be used for treating deficiency of liver and kidney, dizziness, soreness of waist and knees, and flaccidity of tendons and bones.
The fruit and vegetable powder is produced with fresh fruit and vegetable and through 10 steps including pre-treatment, fast freezing, vacuum drying, ultraviolet ray disinfection, packing, storing, etc. Can be almost applied to various fields of food processing, can be used for improving the nutrition components of products, improving the color, the flavor and the like of the products.
The invention carries out scientific proportion on the gynura procumbens, the kudzuvine root, the stevia rebaudiana, the eucommia ulmoides leaf and the fruit and vegetable powder to obtain the composition for reducing the hyperuricemia.
Further, the fruit and vegetable powder is at least one of roxburgh rose powder, apple powder and acerola cherry powder.
The second purpose of the invention is to provide a preparation method of the composition for reducing hyperuricemia, which comprises the following steps:
cleaning Gynura procumbens, radix Puerariae, stevia rebaudiana and folium Eucommiae, removing impurities, and pulverizing the Gynostemma procumbens, radix Puerariae, stevia rebaudiana and folium Eucommiae according to the formula;
adding mixed enzyme and purified water into the crushed materials to obtain mixed solution, adding a pH regulator to adjust the pH to 4.0-5.0, performing frequency-conversion ultrasonic auxiliary enzymolysis extraction at 40-50 ℃, firstly treating for 10-15min at a low-frequency ultrasonic frequency of 30-40kHz, and then treating for 15-20min at a high-frequency ultrasonic frequency of 70-80 kHz; boiling for 5-6min, inactivating enzyme to obtain extractive solution;
filtering the obtained extract with 200-300 mesh gauze, concentrating the obtained filtrate under reduced pressure to 1/3-1/2 of the original volume, adding 3-5 times of 50% -70% ethanol into the concentrated solution, precipitating with ethanol, centrifuging, and freeze drying to obtain Chinese medicinal extract composite powder;
mixing the traditional Chinese medicine extract composite powder and the fruit and vegetable powder to obtain the composition for reducing hyperuricemia.
Further, the mixed enzyme is cellulase R-10 and eductase R-10, wherein the mass ratio of the cellulase R-10 to the eductase R-10 is 2-3:1, and the mixed enzyme accounts for 1% -2% of the total weight of the mixed solution.
Cellulase R-10 is a species of cellulase derived from Trichoderma viride. Cellulase R-10 is an enzyme mixture comprising cellulases, hemicellulases, pectinases and proteases. The eduction enzyme R-10 is a maceration enzyme derived from rhizopus enzyme, contains high pectase and hemicellulase activity, is compatible with the cellulase R-10 and the eduction enzyme R-10, and is matched with frequency conversion ultrasound to assist enzymolysis so that the mixed enzyme is fully contacted with the raw medicinal material, the enzymolysis is utilized to effectively destroy the cell wall structure of the raw medicinal material, and the effective components in the raw medicinal material can be fully released under the assistance of the frequency conversion ultrasound. When the traditional raw medicinal materials are extracted, 2-3 times of water decoction extraction are generally adopted in industrial mass production, the consumption of water and energy sources is high, and the production cost is high.
Further, the pH regulator is at least one of citric acid, lactic acid and malic acid. The enzyme activities of the cellulase R-10 and the eduction enzyme R-10 can be fully exerted by adjusting the pH value of the enzymolysis environment to be between 4.0 and 5.0 by using a pH regulator.
Further, the mass ratio of the crushed material to the purified water is 1:6-10.
Further, the centrifugal speed is 4000-6000rpm, and the centrifugal time is 3-5min.
The invention also aims to provide an application of the composition for reducing hyperuricemia in preparing medicines, health-care foods or functional foods for preventing and treating hyperuricemia.
The invention has the beneficial effects that:
1. the invention carries out scientific proportion on the gynura procumbens, the kudzuvine root, the stevia rebaudiana, the eucommia ulmoides leaf and the fruit and vegetable powder to obtain the composition for reducing the hyperuricemia.
2. The invention also provides a preparation method of the composition for reducing the hyperuricemia, which has low production cost and effectively saves energy consumption. When the traditional raw medicinal materials are extracted, 2-3 times of water decoction and extraction are generally adopted in industrial mass production, the consumption of water and energy sources is high, and the production cost is high.
Detailed Description
In order to make the purposes, technical solutions and some points of the embodiments of the present invention more clear, the technical solutions of the present invention will be clearly and completely described below in conjunction with the detailed description of the present invention. In the present invention, unless otherwise specified, all preparation materials and equipment are commercially available products well known to those skilled in the art.
The invention provides a composition for reducing hyperuricemia, which comprises the following components in parts by weight: 10-25 parts of gynura procumbens, 10-15 parts of radix puerariae, 8-12 parts of stevia rebaudiana, 5-15 parts of eucommia ulmoides leaves and 0.1-3 parts of fruit and vegetable powder.
Preferably, in the present invention, the hyperuricemic composition consists of the following components in parts by weight: 20 parts of gynura procumbens, 12 parts of radix puerariae, 10 parts of stevia rebaudiana, 10 parts of eucommia ulmoides leaves and 1 part of fruit and vegetable powder.
In the formula, the gynura procumbens, the kudzuvine roots and the eucommia leaves are all medicinal and edible raw materials, the stevia rebaudiana and the fruit and vegetable powder are food raw materials, and the composition formula can not generate toxic or side effect after long-term use, is safer to use and has a good function of reducing hyperuricemia.
In the invention, the fruit and vegetable powder is at least one of roxburgh rose powder, apple powder and acerola cherry powder.
The invention also provides a preparation method of the composition for reducing hyperuricemia, which comprises the following steps:
cleaning Gynura procumbens, radix Puerariae, stevia rebaudiana and folium Eucommiae, removing impurities, and pulverizing the Gynostemma procumbens, radix Puerariae, stevia rebaudiana and folium Eucommiae according to the formula;
adding mixed enzyme and purified water into the crushed materials to obtain mixed solution, adding a pH regulator to adjust the pH to 4.0-5.0, performing frequency-conversion ultrasonic auxiliary enzymolysis extraction at 40-50 ℃, firstly treating for 10-15min at a low-frequency ultrasonic frequency of 30-40kHz, and then treating for 15-20min at a high-frequency ultrasonic frequency of 70-80 kHz; boiling for 5-6min, inactivating enzyme to obtain extractive solution;
filtering the obtained extract with 200-300 mesh gauze, concentrating the obtained filtrate under reduced pressure to 1/3-1/2 of the original volume, adding 3-5 times of 50% -70% ethanol into the concentrated solution, precipitating with ethanol, centrifuging, and freeze drying to obtain Chinese medicinal extract composite powder;
mixing the traditional Chinese medicine extract composite powder and the fruit and vegetable powder to obtain the composition for reducing hyperuricemia.
Wherein, the gynura procumbens, the kudzuvine root, the stevia rebaudiana and the eucommia ulmoides leaves are crushed and then are screened, and the screening mesh number is 40-60 meshes, preferably 60 meshes.
In the invention, when the crushed material is added with the mixed enzyme and the purified water to obtain the mixed solution, the purified water and the crushed material are preferably uniformly mixed, and then the mixed enzyme is added, so that the enzyme activity failure of the mixed enzyme due to the environmental influence can be effectively avoided; after the mixed solution is obtained, a pH regulator is added to regulate the pH value of the mixed solution to 4.0-5.0, and the pH regulator is preferably added in a dropwise manner, wherein the pH value is preferably 4.8, and the mixed enzyme has better enzyme activity under the condition of the pH value of 4.8.
When the mixed solution is subjected to enzymolysis, the mixed solution is preferably subjected to enzymolysis in a constant-temperature water bath, the enzymolysis temperature is preferably 45 ℃, and the enzyme activity of the mixed enzyme is better at the moment, so that the mixed solution has a better enzymolysis effect. During enzymolysis, the ultrasonic frequency conversion is matched to assist enzymolysis extraction, high-energy kinetic energy is generated by utilizing ultrasonic waves, so that the kinetic energy obtained by the mixed enzyme is fully contacted with the raw materials, the enzymolysis is more sufficient, the cell wall structure of the raw materials is damaged, the migration speed of the effective components in the raw materials is accelerated, and the purpose of extraction is achieved.
Preferably, during the enzymolysis extraction assisted by variable frequency ultrasound, the enzymolysis extraction is firstly carried out for 12min at a low frequency ultrasonic frequency of 35kHz, and then the enzymolysis extraction is carried out for 18min at a high frequency ultrasonic frequency of 75 kHz; boiling for 5min, and inactivating enzyme to obtain extractive solution. In industrial mass production, 2-3 times of water decoction and extraction are generally adopted, so that the consumption of water and energy sources is high, and the production cost is high.
Filtering the obtained extract with 200-300 mesh gauze, preferably 300 mesh, filtering to remove the residue, concentrating the filtrate under reduced pressure to 1/3-1/2 of the original volume, adding 3-5 times of 50% -70% ethanol, precipitating with ethanol, centrifuging, and lyophilizing to obtain the final product; wherein, during the alcohol precipitation, ethanol with the volume fraction of 4 times and 60% is preferred for alcohol precipitation, and the total flavonoids which are the effective components in the enzymolysis liquid can be effectively collected through alcohol precipitation. Centrifugation and freeze-drying are carried out according to procedures well known to those skilled in the art.
In the invention, the mixed enzyme is cellulase R-10 and eductase R-10, wherein the mass ratio of the cellulase R-10 to the eductase R-10 is 2-3:1, and the mixed enzyme accounts for 1% -2% of the total weight of the mixed solution. Preferably, the mass ratio of the cellulase R-10 to the eductase R-10 is 2:1, and the mixed enzyme accounts for 1.5% of the total weight of the mixed solution. The plant cell wall components of the raw medicinal materials mainly comprise cellulose, hemicellulose, lignin, pectin, mucopolysaccharide and the like, the components are complex, and the cell wall of the raw medicinal materials cannot be effectively destroyed by enzymolysis by single enzyme, so that the cellulase R-10 and the eduction enzyme R-10 are selected from a plurality of enzyme types for compatibility and use, and the enzymolysis effect is good.
In the invention, the pH regulator is at least one of citric acid, lactic acid and malic acid.
In the invention, the mass ratio of the crushed material to the purified water is 1:6-10. Preferably, the mass ratio of the crushed material to the purified water is 1:8. the adding amount of the purified water is not too large or too small, the enzymolysis contact is insufficient due to the excessive adding amount of the purified water, and meanwhile, the time required for the subsequent concentration is longer, so that the production cost is not saved; if the addition amount of the purified water is too small, the crushed materials cannot be fully dispersed, which is unfavorable for the full progress of enzymolysis.
In the invention, the centrifugal speed is 4000-6000rpm, and the centrifugal time is 3-5min.
The invention also provides application of the composition for reducing hyperuricemia in preparing medicines, health-care foods or functional foods for preventing and treating hyperuricemia.
For further explanation of the present invention, the following describes in detail, with reference to examples, a composition for reducing hyperuricemia, and a preparation method and application thereof, which are not to be construed as limiting the scope of the present invention.
The experimental methods in the following examples are conventional methods unless otherwise specified. The invention is further illustrated by the following examples:
example 1: composition for preparing hyperuricemia-reducing agent
Cleaning gynura procumbens, kudzuvine root, stevia rebaudiana and eucommia ulmoides leaves, removing impurities, and taking 20 parts of gynura procumbens, 12 parts of kudzuvine root, 10 parts of stevia rebaudiana and 10 parts of eucommia ulmoides leaves for crushing;
adding 8 times of purified water, cellulase R-10 and educing enzyme R-10 into the crushed material to obtain mixed solution, wherein the adding amount of the cellulase R-10 is 1.0% of the total amount of the mixed solution, the adding amount of the educing enzyme R-10 is 0.5% of the total amount of the mixed solution, adding citric acid to adjust pH to 4.8, performing frequency-conversion ultrasonic auxiliary enzymolysis extraction at 45 ℃, firstly treating for 12min at a low-frequency ultrasonic frequency of 35kHz, and then treating for 18min at a high-frequency ultrasonic frequency of 75 kHz; boiling for 5min, inactivating enzyme to obtain extractive solution;
filtering the obtained extract with 300 mesh gauze, concentrating the obtained filtrate under reduced pressure to 1/3-1/2 of the original volume, adding 4 times of 60% ethanol for precipitating with ethanol, centrifuging at 5000rpm for 5min, and lyophilizing to obtain Chinese medicinal extract composite powder;
mixing the traditional Chinese medicine extract composite powder and 1 part of acerola cherry powder to obtain the composition for reducing the hyperuricemia.
Example 2: composition for preparing hyperuricemia-reducing agent
Cleaning gynura procumbens, kudzuvine root, stevia rebaudiana and eucommia ulmoides leaves, removing impurities, and taking 10 parts of gynura procumbens, 15 parts of kudzuvine root, 8 parts of stevia rebaudiana and 15 parts of eucommia ulmoides leaves for crushing treatment;
adding 10 times of purified water, cellulase R-10 and educing enzyme R-10 into the crushed material to obtain mixed solution, wherein the adding amount of the cellulase R-10 is 1.5% of the total amount of the mixed solution, the adding amount of the educing enzyme R-10 is 0.5% of the total amount of the mixed solution, adding citric acid to adjust pH to 4.0, performing frequency-conversion ultrasonic auxiliary enzymolysis extraction at 40 ℃, firstly treating for 10min according to the low-frequency ultrasonic frequency of 40kHz, and then treating for 18min according to the high-frequency ultrasonic frequency of 80 kHz; boiling for 6min, inactivating enzyme to obtain extractive solution;
filtering the obtained extract with 200 mesh gauze, concentrating the obtained filtrate under reduced pressure to 1/3-1/2 of the original volume, adding 5 times of 50% ethanol for precipitating with ethanol, centrifuging at 4000rpm for 5min, and lyophilizing to obtain the traditional Chinese medicine extract composite powder;
mixing 3 parts of traditional Chinese medicine extract composite powder and apple powder to obtain the composition for reducing hyperuricemia.
Example 3: composition for preparing hyperuricemia-reducing agent
Cleaning gynura procumbens, kudzuvine root, stevia rebaudiana and eucommia ulmoides leaves, removing impurities, and taking 25 parts of gynura procumbens, 10 parts of kudzuvine root, 12 parts of stevia rebaudiana and 5 parts of eucommia ulmoides leaves for crushing treatment;
adding 6 times of purified water, cellulase R-10 and educing enzyme R-10 into the crushed material to obtain mixed solution, wherein the adding amount of the cellulase R-10 is 1.2% of the total amount of the mixed solution, the adding amount of the educing enzyme R-10 is 0.6% of the total amount of the mixed solution, adding citric acid to adjust pH to 5.0, performing frequency-conversion ultrasonic-assisted enzymolysis extraction at 50 ℃, firstly treating for 15min at a low-frequency ultrasonic frequency of 30kHz, and then treating for 20min at a high-frequency ultrasonic frequency of 70 kHz; boiling for 6min, inactivating enzyme to obtain extractive solution;
filtering the obtained extract with 200 mesh gauze, concentrating the filtrate under reduced pressure to 1/3-1/2 of the original volume, adding 3 times of 70% ethanol into the concentrated solution, precipitating with ethanol, centrifuging at 6000rpm for 4min, and lyophilizing to obtain the traditional Chinese medicine extract composite powder;
mixing the traditional Chinese medicine extract composite powder and 2 parts of roxburgh rose powder to obtain the composition for reducing hyperuricemia.
Comparative example 1: the same procedure as in example 1 was followed except that the enzyme R-10 was not used on the basis of example 1.
Comparative example 2: the procedure of example 1 was followed except that cellulase R-10 was not used in the procedure of example 1.
Comparative example 3:
cleaning gynura procumbens, kudzuvine root, stevia rebaudiana and eucommia ulmoides leaves, removing impurities, and taking 20 parts of gynura procumbens, 12 parts of kudzuvine root, 10 parts of stevia rebaudiana and 10 parts of eucommia ulmoides leaves for crushing;
adding 8 times of purified water, cellulase R-10 and educing enzyme R-10 into the crushed material to obtain mixed solution, wherein the adding amount of the cellulase R-10 is 1.0% of the total amount of the mixed solution, the adding amount of the educing enzyme R-10 is 0.5% of the total amount of the mixed solution, adding citric acid to adjust the pH value to 4.8, and performing enzymolysis at 45 ℃ for 30min; boiling for 5min, inactivating enzyme to obtain extractive solution;
filtering the obtained extract with 300 mesh gauze, concentrating the obtained filtrate under reduced pressure to 1/3-1/2 of the original volume, adding 4 times of 60% ethanol for precipitating with ethanol, centrifuging at 5000rpm for 5min, and lyophilizing to obtain Chinese medicinal extract composite powder;
mixing the traditional Chinese medicine extract composite powder and 1 part of acerola cherry powder to obtain the composition for reducing the hyperuricemia.
Comparative example 4:
cleaning gynura procumbens, kudzuvine root, stevia rebaudiana and eucommia ulmoides leaves, removing impurities, and taking 20 parts of gynura procumbens, 12 parts of kudzuvine root, 10 parts of stevia rebaudiana and 10 parts of eucommia ulmoides leaves for crushing;
adding 8 times of purified water, cellulase R-10 and educing enzyme R-10 into the crushed material to obtain mixed solution, wherein the adding amount of the cellulase R-10 is 1.0% of the total amount of the mixed solution, the adding amount of the educing enzyme R-10 is 0.5% of the total amount of the mixed solution, adding citric acid to adjust pH to 4.8, performing ultrasonic-assisted enzymolysis extraction at 45 ℃, and treating for 30min at an ultrasonic frequency of 35 kHz; boiling for 5min, inactivating enzyme to obtain extractive solution;
filtering the obtained extract with 300 mesh gauze, concentrating the obtained filtrate under reduced pressure to 1/3-1/2 of the original volume, adding 4 times of 60% ethanol for precipitating with ethanol, centrifuging at 5000rpm for 5min, and lyophilizing to obtain Chinese medicinal extract composite powder;
mixing the traditional Chinese medicine extract composite powder and 1 part of acerola cherry powder to obtain the composition for reducing the hyperuricemia.
Comparative example 5:
cleaning gynura procumbens, kudzuvine root, stevia rebaudiana and eucommia ulmoides leaves, removing impurities, and taking 20 parts of gynura procumbens, 12 parts of kudzuvine root, 10 parts of stevia rebaudiana and 10 parts of eucommia ulmoides leaves for crushing;
adding 8 times of purified water, cellulase R-10 and educing enzyme R-10 into the crushed material to obtain mixed solution, wherein the adding amount of the cellulase R-10 is 1.0% of the total amount of the mixed solution, the adding amount of the educing enzyme R-10 is 0.5% of the total amount of the mixed solution, adding citric acid to adjust pH to 4.8, performing ultrasonic-assisted enzymolysis extraction at 45 ℃, and treating for 30min at an ultrasonic frequency of 75 kHz; boiling for 5min, inactivating enzyme to obtain extractive solution;
filtering the obtained extract with 300 mesh gauze, concentrating the obtained filtrate under reduced pressure to 1/3-1/2 of the original volume, adding 4 times of 60% ethanol for precipitating with ethanol, centrifuging at 5000rpm for 5min, and lyophilizing to obtain Chinese medicinal extract composite powder;
mixing the traditional Chinese medicine extract composite powder and 1 part of acerola cherry powder to obtain the composition for reducing the hyperuricemia.
Comparative example 6:
cleaning gynura procumbens, kudzuvine root, stevia rebaudiana and eucommia ulmoides leaves, removing impurities, and taking 20 parts of gynura procumbens, 12 parts of kudzuvine root, 10 parts of stevia rebaudiana and 10 parts of eucommia ulmoides leaves for crushing;
adding 8 times of purified water, cellulase R-10 and educing enzyme R-10 into the crushed material to obtain mixed solution, wherein the adding amount of the cellulase R-10 is 1.0% of the total amount of the mixed solution, the adding amount of the educing enzyme R-10 is 0.5% of the total amount of the mixed solution, adding citric acid to adjust pH to 4.8, performing ultrasonic-assisted enzymolysis extraction at 45 ℃, and treating for 30min at an ultrasonic frequency of 75 kHz; boiling for 5min, inactivating enzyme to obtain extractive solution;
filtering the obtained extract with 300 mesh gauze, concentrating the filtrate under reduced pressure to 1/3-1/2 of the original volume, centrifuging at 5000rpm for 5min, and lyophilizing to obtain the traditional Chinese medicine extract composite powder;
mixing the traditional Chinese medicine extract composite powder and 1 part of acerola cherry powder to obtain the composition for reducing the hyperuricemia.
Test example 1:
calculating the total flavone content and the conversion rate of the total flavone of the hyperuricemia reducing compositions prepared in examples 1-3 and comparative examples 1-6, wherein the method for detecting the total flavone refers to fifteen in the guidelines for health food physicochemical and health index detection and evaluation technology (2020 edition), and the calculation formula of the conversion rate of the total flavone is as follows: total flavone transfer rate (%) =total flavone content in extract/total flavone content in medicinal material×100%, and the results are shown in table 1.
TABLE 1
| Group of | Total flavone content, mg/g | Total flavone transfer rate% |
| Example 1 | 11.34 | 90.24 |
| Example 2 | 10.25 | 88.63 |
| Example 3 | 11.07 | 89.58 |
| Comparative example 1 | 6.46 | 50.37 |
| Comparative example 2 | 7.15 | 56.91 |
| Comparative example 3 | 8.32 | 65.38 |
| Comparative example 4 | 9.50 | 76.12 |
| Comparative example 5 | 9.88 | 78.49 |
| Comparative example 6 | 9.39 | 73.73 |
As can be seen from Table 1, the total flavone content of the hyperuricemic compositions prepared in examples 1-3 averaged 10.88mg/g, and the total flavone transfer rate was 89.48%, and it can be seen that the total flavone extraction rate was higher.
After the comparative examples 1 and 2 were not added with the educt enzyme R-10 and the cellulase R-10, the total flavone content of the prepared composition for reducing the hyperuricemia was 6.46mg/g and 7.15mg/g, respectively, and the transfer rate of the total flavone was 50.37% and 56.91%, respectively, which indicates that the educt enzyme R-10 and the cellulase R-10 have better synergistic effect, and the total flavone content of the prepared composition for reducing the hyperuricemia was higher.
After the comparative example 3 does not adopt ultrasonic auxiliary enzymolysis, the total flavone content of the prepared composition for reducing the hyperuricemia is 8.32mg/g, the transfer rate of the total flavone is 65.38 percent, which is lower than that of the example 1 and the comparative examples 4 and 5, and the composition has better extraction effect by the enzymolysis auxiliary frequency conversion ultrasonic extraction.
In comparative example 6, after no alcohol precipitation is adopted, the total flavone content of the prepared composition for reducing the hyperuricemia is 9.39mg/g, and the transfer rate of the total flavone is 73.73%, which indicates that the total flavone as an effective component in the enzymolysis liquid can be effectively collected through alcohol precipitation.
Test example 2: effect of hyperuricemia-reducing composition on rat hyperuricemia
2.1 Experimental materials
2.1.1 experimental animals: SD rats, male, 140-160 g,60 purchased from Beijing Vitre Lihua laboratory animal technologies Co., ltd., license number: SCXK (jing) 2016-0011.
2.2.2 drugs: the hyperuricemic composition prepared in example 1, benzbromarone (Heman, germany, lot number: 1513419); adenine (Sigma, lot # WXBB 0585V); ethambutol (Shenyang red flag pharmaceutical, lot number 1510121), CMC-Na (Shanghai Zhaoyun chemical industry, lot number 170410).
2.2 Experimental methods
2.2.1 grouping and administration
The male rats were randomly divided into a normal group, a model group, a high, medium and low dose group of solid drink, 6 groups, and 10 groups each; the animals of the normal group and the model group are subjected to gastric lavage and administration at the same time point every day, and the respective administration groups are subjected to gastric lavage with corresponding medicines, (the high, medium and low dosage of the composition for reducing hyperuricemia prepared in the example 1 is respectively 4.8g crude drug/kg, 2.4g crude drug/kg, 1.2g crude drug/kg, and the dosage of the tribromoron is 20mg/kg, and the composition is prepared by pure water), and the gastric lavage volumes are 10ml/kg, and the continuous gastric lavage is carried out for 9 days.
2.2.2 establishment of hyperuricemia model
Adenine is prepared into suspension by 0.5% CMC-Na, the dosage is 100mg/kg, ethambutol is prepared by pure water, the dosage is 250mg/kg, the corresponding medicine is infused into the stomach at the same time point of afternoon every day for molding, other animals are infused with gastric adenine (volume 5 ml/kg) and ethambutol (volume 5 ml/kg) except for normal animals which are infused with the stomach 0.5% CMC-Na (volume 10 ml/kg), continuous molding is carried out for 6 days (first molding is started after 3 days of prior administration), 1h after the last molding, blood is taken from vein plexus of the back of eye orbit of all animals for about 1ml, and serum is separated by centrifugation for 10min at 3500r/min after standing for 1h at room temperature.
2.2.3 detection index
Uric Acid (UA), creatinine (CREA) and urea nitrogen (BUN) levels in serum were measured using a fully automated biochemical analyzer.
After the animals blood is collected, rapidly removing the neck and killing the animals, rapidly separating kidney tissues on an ice table, removing membranes and medulla from the right kidney, dividing the kidney into halves, freezing half of the kidney tissues by liquid nitrogen, storing the half of the kidney tissues at-80 ℃ for protein measurement, immediately shearing the other half of the kidney tissues on the ice table, and storing the other half of the kidney tissues at-80 ℃ for RNA extraction; meanwhile, the left kidney of the animal is peeled off, the surface fat is removed, and the animal is soaked in 4% formalin for observing histopathological sections. The results are shown in Table 2.
Table 2 influence of gynura procumbens solid drink on hyperuricemia rats (x±s, n=10)
Note that: comparing with model group, P < 0.05, P < 0.01, comparing with normal group, deltaP < 0.05,
△△ P＜0.01
as can be seen from Table 2, the weight of the animals in the other groups was reduced, serum Creatinine (CREA) and urea nitrogen (BUN) were elevated, and the animals in the model group had significant differences (P < 0.01), and serum Uric Acid (UA) was significantly elevated (P < 0.01) compared with that in the normal group, indicating that the preparation of the rat kidney excretion disorder type hyperuricemia model was successful.
The serum uric acid levels were reduced in all animals dosed as compared to the model group, and in the high and medium doses (4800, 2400mg crude drug/kg) and in the phenylbromarone (20 mg/kg) animals, except the low dose group (1200 mg crude drug/kg), the serum uric acid levels were significantly reduced (P < 0.05). Demonstrating that the high uric acid lowering composition prepared in example 1 can significantly lower animal serum uric acid level in high and medium dose groups.
All dosing groups showed reduced serum Creatinine (CREA) and urea nitrogen (BUN) levels compared to the model group, and the high dose group (4800 mg crude drug/kg, 20% yield) showed significant reductions (P < 0.05 or P < 0.01) in serum Creatinine (CREA) and urea nitrogen (BUN) levels. Demonstrating that the hyperuricemic composition prepared in example 1 has some protective effect on renal excretion.
Finally, it should also be noted that the above list is merely a few specific embodiments of the present invention. Obviously, the invention is not limited to the above embodiments, but many variations are possible. All modifications directly derived or suggested to one skilled in the art from the present disclosure should be considered as being within the scope of the present invention.
Claims (8)
1. A composition for reducing hyperuricemia, characterized in that: the composite material consists of the following components in parts by weight: 10-25 parts of gynura procumbens, 10-15 parts of radix puerariae, 8-12 parts of stevia rebaudiana, 5-15 parts of eucommia ulmoides leaves and 0.1-3 parts of fruit and vegetable powder.
2. The hyperuricemia reducing composition according to claim 1, wherein the fruit and vegetable powder is at least one of fructus Rosae Normalis powder, fructus Mali Pumilae powder, and acerola powder.
3. A method for preparing a composition for reducing hyperuricemia, which is characterized by comprising the following steps:
cleaning Gynura procumbens, radix Puerariae, stevia rebaudiana and folium Eucommiae, removing impurities, and pulverizing the Gynostemma procumbens, radix Puerariae, stevia rebaudiana and folium Eucommiae according to the formula;
adding mixed enzyme and purified water into the crushed materials to obtain mixed solution, adding a pH regulator to adjust the pH to 4.0-5.0, performing frequency-conversion ultrasonic auxiliary enzymolysis extraction at 40-50 ℃, firstly treating for 10-15min at a low-frequency ultrasonic frequency of 30-40kHz, and then treating for 15-20min at a high-frequency ultrasonic frequency of 70-80 kHz; boiling for 5-6min, inactivating enzyme to obtain extractive solution;
filtering the obtained extract with 200-300 mesh gauze, concentrating the obtained filtrate under reduced pressure to 1/3-1/2 of the original volume, adding 3-5 times of 50% -70% ethanol into the concentrated solution, precipitating with ethanol, centrifuging, and freeze drying to obtain Chinese medicinal extract composite powder;
mixing the traditional Chinese medicine extract composite powder and the fruit and vegetable powder to obtain the composition for reducing hyperuricemia.
4. The method for preparing the composition for reducing hyperuricemia according to claim 3, wherein the mixed enzyme is cellulase R-10 and eductase R-10, wherein the mass ratio of the cellulase R-10 to the eductase R-10 is 2-3:1, and the mixed enzyme accounts for 1% -2% of the total weight of the mixed solution.
5. A method for preparing a hyperuricemic composition according to claim 3, wherein the pH adjuster is at least one of citric acid, lactic acid and malic acid.
6. A method for preparing a hyperuricemic composition according to claim 3, wherein the mass ratio of the crushed material to purified water is 1:6-10.
7. A method for preparing a hyperuricemic composition according to claim 3, wherein the centrifugation speed is 4000-6000rpm and the centrifugation time is 3-5min.
8. Use of the hyperuricemia-reducing composition according to claim 1 or 2 or the hyperuricemia-reducing composition prepared by the preparation method according to any one of claims 3 to 7 in the preparation of a medicament, health food or functional food for preventing and treating hyperuricemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311800998.9A CN117752711A (en) | 2023-12-26 | 2023-12-26 | Composition for reducing hyperuricemia as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311800998.9A CN117752711A (en) | 2023-12-26 | 2023-12-26 | Composition for reducing hyperuricemia as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117752711A true CN117752711A (en) | 2024-03-26 |
Family
ID=90316140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311800998.9A Pending CN117752711A (en) | 2023-12-26 | 2023-12-26 | Composition for reducing hyperuricemia as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117752711A (en) |
-
2023
- 2023-12-26 CN CN202311800998.9A patent/CN117752711A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109846940A (en) | A kind of Siberian solomonseal rhizome polysaccharide extract and its extracting method and purposes | |
| CN103653144B (en) | Healthcare drink capable of improving immunity and preparation method thereof | |
| CN104667021A (en) | Compound product containing bamboo leaf flavonoid and preparation method thereof | |
| CN104906361A (en) | Hypolipidemic yellow rice wine and making method thereof | |
| CN105996028A (en) | Ginger extract, ginger fiber and preparation method of ginger extract and ginger fiber | |
| CN101664180A (en) | Health-care nutritional complexing agent with effect of and preparation method thereof | |
| CN112515014A (en) | Kudzuvine root polysaccharide sweet zong black tea and preparation method thereof | |
| CN102511876B (en) | Hawthorn red jujube thick syrup and production process thereof | |
| CN106581166A (en) | Anti-fatigue food, health product or pharmaceutical composition | |
| CN107596112A (en) | A kind of kidney tonifying tea prescription and preparation method thereof | |
| CN108450941A (en) | A kind of dietary composition adjusting lipid metaboli | |
| CN117752711A (en) | Composition for reducing hyperuricemia as well as preparation method and application thereof | |
| CN107668272A (en) | A kind of lowering blood-fat and reducing weight lotus leaf tea | |
| CN107467654B (en) | Kelp and sea cucumber compound extract and preparation method and application thereof | |
| KR101381277B1 (en) | The wild rice gel containing ginseng | |
| CN109805235B (en) | Wheat-flavor composite polypeptide solid beverage for assisting in reducing hypertension, hyperglycemia and hyperlipidemia, and preparation method and application thereof | |
| CN108969580B (en) | Preparation method and application of blue cloth total tannin | |
| CN105087284A (en) | Compound raspberry health wine and preparation method thereof | |
| CN109907320A (en) | It is a kind of relieve the effect of alcohol, the composition of toxin expelling, liver protecting and preparation method thereof | |
| CN114668797B (en) | Plant fermentation liquid for resisting oxidation, reducing blood fat and protecting liver as well as preparation method and application thereof | |
| CN115381874B (en) | Traditional Chinese medicine composition and granule for treating chicken noninfectious diarrhea and preparation method thereof | |
| CN114931214B (en) | Chinese herbal medicine composition for improving hearing impairment and preparation method and application thereof | |
| CN108159162B (en) | Fermentation product containing magnolia bark bulk drug and preparation method and application thereof | |
| CN101912449B (en) | Medicament for treating hepatitis and preparation technology thereof | |
| KR20100129040A (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |